The NFL Players Association and the National Football League are learning more about the potential cannabis and its components, such as CBD, possess as alternative treatments for pain. This is in addition to finding out how the use of marijuana affects athletic performance.
Last week, a notice was made public by the joint organizations’ committee. It states that the league’s objective is to find investigators who possess the ability to conduct studies whose goal will be to add to the Pain Management Committee’s knowledge about athletic performance and pain management in players of the NFL.
Apart from focusing on the effects of marijuana or its derivatives on athletic performance, the NFL-NFLPA committee noted that last year it held two forums on cannabinoids to learn more about the science behind cannabinoids and how they’re manufactured in North America. However, the forums’ findings were inconclusive as the Pain Management Committee (“PMC”) discovered that, while CBD has potential to provide pain relief, science at the moment lacks evidence to support these claims.
In a paper for the players, the committee noted that while cannabinoids were a promising component, most hype surrounding it was based upon various results from animal studies. As part of a bargaining agreement, the league also changed its policy on drug testing. The new policy does not allow for suspension of NFL players from games over positive tests for any drug, including cannabis.
This decision demonstrates a considerable shift in the league’s approach to drug use by its players, with the agreement highlighting the need to concentrate on treatment and evaluation rather than punishing players.
Currently, players who self-refer themselves, show any behaviors that demonstrate drug misuse or test positive for drugs will be required to join an intervention program where they will be evaluated and receive a treatment plan. After that point, testing positive would be met with a half-week loss of salary for beginner violations, loss of a week’s salary for second violations, and an additional week’s salary loss for third violations. Any violations after that would result in a three-week salary loss.
The NBA is showing similar tendencies. Earlier in December, the league’s top official stated that an interim policy by the NBA to stop randomly testing players for cannabis amid the COVID-19 pandemic may be made permanent. Commissioner Adam Silver explained that instead of conducting blanket tests, the league would reach out to any player who demonstrated signs of problematic dependency rather than players who used cannabis casually.
In Canada where marijuana is legal at a national level, Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) entered a partnership with a plant breeding and analytics company called Phenome One. This partnership has allowed Pac Roots to gain access to top-shelf cannabis genetics, which it uses to produce premium-quality products.
NOTE TO INVESTORS: The latest news and updates relating to Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) are available in the company’s newsroom at http://cnw.fm/PACR
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.